Published online Oct 6, 2024. doi: 10.12998/wjcc.v12.i28.6230
Revised: July 9, 2024
Accepted: July 17, 2024
Published online: October 6, 2024
Processing time: 69 Days and 2.3 Hours
Sarcomatoid renal cell carcinoma (SRCC) is a rare variant of renal cell carcinoma associated with an unfavorable prognosis. The efficacy of conventional chemo
A 77-year-old female patient was referred to our hospital following the incidental detection of a right kidney tumor without specific symptoms. The tumor was successfully resected, and subsequent pathological examination confirmed SRCC. She experienced both local recurrence and distant metastasis eight months after the initial laparoscopic resection. Following six cycles of toripalimab combined with pirarubicin chemotherapy, the patient achieved a partial response. Subse
Combination therapy with programmed death 1 antibodies and cytotoxic agents may be a recommended first-line treatment approach for SRCC.
Core Tip: Sarcomatoid renal cell carcinoma (SRCC) is a highly aggressive and uncommon malignant tumor of the kidney, which is associated with a rapid clinical course and unfavorable prognosis compared to conventional RCC. Traditional chemotherapy and targeted therapies have limited efficacy against SRCC. We present a rare case of recurrent and metastatic SRCC that achieved excellent outcomes with the combination of immunotherapy and chemotherapy. This report sheds new light on diagnostic and therapeutic approaches for SRCC.